1551 results about "Peptide fragment" patented technology

Disclosed is a novel Lepidopteran- and Coleopteran-active delta-endotoxin polypeptide, and compositions comprising the polypeptide, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that comprise nucleic acid segments encoding the polypeptide. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising the novel sequences of the invention, as well as methods for controlling an insect population, such as the Western Corn Rootworm and Colorado potato beetle, and for conferring to a plant population resistance to the target insect species.

Disclosed are novel insecticidal polypeptides, and compositions comprising these polypeptides, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that contain nucleic acid segments that encode the disclosed delta-endotoxin polypeptides. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising these polynucleotide sequences, as well as methods for controlling an insect population, such as Colorado potato beetle, southern corn rootworm and western corn rootworm, and for conferring to a plant resistance to a target insect species.

The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.

The invention provides PEDF peptides which retain the biological activity of full-length PEDF. Fusion proteins comprising a PEDF peptide are also provided. The invention further provides a codon-optimized PEDF coding sequence and method of expressing it in bacteria. Compositions, methods of use and kits are also provided.

A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A):

-(Pro-X-Gly)_n-   (1)

wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.

Methods are provided for efficient, high throughput screening of antibody libraries against proteins targets, especially membrane proteins. In particular, methods are provided for screening a fully human antibody library against membrane proteins such as HIV coreceptors in yeast. More particularly, a library of human single chain antibodies is screened against peptide fragments derived from extracellular domains of human CCR5 and high affinity monoclonal antibodies against CCR5 are selected.

The present invention provides receptors for the growth differentiation factor (GDF) family of growth factors and methods of identifying such receptors. Also included are methods of identifying antibodies which bind to the receptors, peptide fragments of the receptor which inhibit GDF binding, GDF receptor-binding agents capable of blocking GDF binding to the receptor. The receptors of the invention allow the identification of antagonists or agonists useful for agricultural and human therapeutic purposes.

The invention relates to a synthetic method for a magnetic metal organic framework composite material coated by [Cu2(btc)2] on surfaces of ferroferric oxide microspheres and application of the composite material. The method comprises the following steps of: firstly synthesizing ferroferric oxide microspheres by a hydrothermal synthesis method; dispersing magnetic spheres in an ethanol liquid of mercaptoacetic acid, wherein hydroxyls are formed on the surface of the spheres; dispersing mercaptoacetic acid modified magnetic spheres to an ethanol liquid of copper acetate, reacting for 15 minutes at 70 DEG C, and then dispersing the product in an ethanol liquid of trimesic acid and reacting for 30 minutes at 70 DEG C; and performing alternate reaction of magnetic spheres with copper acetate and the ethanol liquid of trimesic acid to finally, obtain the magnetic metal organic framework composite material with a core-shell structure. The material has a metal organic framework shell layer and can be coordinated with peptide fragments with amino groups and carboxylic group so as to enrich low concentration peptide. Meanwhile, the enriching and separating process is fast, simple and convenient due to high paramagnetism of ferroferric oxide. The synthetic method is simple and low in cost, and can be used for enrichment and separation of low abundance peptide fragments less than 1nM and MALDI-TOFMS (Matrix-Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometer) detection.

A method of epitope discovery comprising the step of selecting an epitope from a population of peptide fragments of an antigen associated with a target cell, wherein the fragments have a known or predicted affinity for a major histocompatibility complex class I receptor peptide binding cleft, wherein the epitope selected corresponds to a proteasome cleavage product of the target cell.

The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.

This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.

The invention relates to a method for preparing Semaglutide through solid and liquid combination, and solves the technical problems that in the process for synthesizing long-sequence polypeptide by the existing technology, the synthesis period is long; the purification difficulty is high; the yield is low. The method for preparing Semaglutide through solid and liquid combination provided by the invention is characterized in that firstly, Lys and resin are condensed in an Alloc-Lys(Fmoc)-OH form by adopting a solid phase synthesis method; Fmoc protecting groups on epsilon-NH2 are removed; sidechain connection is performed; cracking is performed to obtain Alloc-Lys(PEG-PEG-gamma-Glu(OtBu)-Monobutyl octadecanate)-OH; meanwhile, 10 dipeptide or tripeptide or tetrapeptide fragments are simultaneously synthesized by a liquid phase synthesis method; then, the condensation reaction of the synthesized peptide fragments and single amino acid is performed by using the resin as a carrier; the 15-step solid phase condensation reaction is reduced in the process; the generation of lacked peptide impurities is reduced; the product purity and the yield are improved; meanwhile, the generation of the impurities of [+Gly]-Semaglutide and [+Ala]-Semaglutide is effectively avoided; the purification difficulty is greatly reduced. The method is widely applied to the technical field of polypeptide medicine preparation.

The present invention provides methods for efficiently generating and screening protein libraries for optimal proteins with desired biological functions, such as improved binding affinity for biologically and/or therapeutically important target molecules. The method is performed in silico in a high-throughput fashion by mining the ever-expanding database of protein sequences in all living things, especially humans. In one embodiment, a method of constructing a designer protein library comprises the steps of: providing an amino acid sequence derived from a lead protein, referred to as a lead sequence; comparing the lead sequence with a plurality of test protein sequences; Select at least two peptide fragments having at least 15% sequence identity with the leader sequence from each test protein sequence, and the selected peptide fragments form a selection library; a library of designed proteins is formed by replacing the leader sequence with the selection library. Libraries of designed proteins can be expressed in vitro or in vivo to generate libraries of recombinant proteins that can be screened for new or improved functions relative to lead proteins, such as antibodies against a therapeutically important target.

The invention relates to a new protein quantitative method, in particular to a quantitative method utilizing equiponderance dimethylation marking. The method utilizes the organic combination of methanal and isotope of the methanal, and sodium cyanoborohydride and isotope of the sodium cyanoborohydride for marking peptide fragments, so that the peptide fragments have the similar mass-to-charge ratio on the primary spectrum of the mass spectrum and have the different mass-to-charge ratios on the secondary spectrum of the mass spectrum, and the protein quantitative analysis is achieved on the secondary spectrum. Compared with other quantitative methods, the method has the advantages of being high in quantitative accuracy and precision, and wide in dynamic range.

This invention relates to methods and apparatus for detecting the pattern of post translational modification in a protein or in a plurality of proteins in a sample. One or more target proteins are subjected to predetermined proteolysis to yield plural peptide fragments comprising potential post translational modification sites. The fragments and the state of such sites are analyzed to yield a post translational pattern for the protein or proteins.

The invention discloses a tumor neoantigen detection method and device based on next-generation sequencing, and a storage medium. The tumor neoantigen detection method disclosed by the invention comprises the following steps of variation detection, MHC (Major Histocompatibility Complex) molecular identification, variation annotation, variation peptide fragment prediction, variation peptide fragment MHC/II type affinity prediction, antigen expression abundance detection, clonality analysis and candidate tumor neoantigen comprehensive scoring sorting, wherein the candidate tumor neoantigen comprehensive scoring sorting comprises the step of scoring sorting on the neoantigen according to MHC affinity, antigen expression abundance and clonality according to a formula I. According to the tumorneoantigen detection method, a next-generation sequencing comparison file is used as a basis to carry out mutation and MHC detection, in addition, the candidate tumor neoantigen is scored from three dimensions including MHC I/II type affinity, antigen expression abundance and clonality so as to the screen high-quality tumor neoantigen, and a foundation is laid for immunotherapy on the basis of thetumor neoantigen.

Mycobacterial proteins from culture filtrate or cytosol are disclosed as being useful B cell antigens for early diagnosis of mycobacterial disease, particularly in humans. These proteins include four that had not previously been recognized as B cell antigens (LppZ protein encoded by Mtb gene Rv3006; SodC protein encoded by Mtb gene Rv0432; BfrB protein encoded by Mtb gene Rv3841 and TrxC protein encoded byMtb gene Rv3914). Antigenic compositions include these proteins and/or peptide fragments thereof, in various combinations with each other or with one or more of a set of 10 additional Mtb proteins known to be antigens (in paricular early antigens. Methods and kits for using these antigenic composition for early diagnosis of mycobacterial infection and disease are also disclosed.

The invention discloses a method of establishing liquid chromatography-mass spectrometry (LC-MS) analysis of a royal jelly sensitized protein. The method comprises the following steps: carrying out electrophoresis analysis on royal jelly proteins, preprocessing the sensitized protein bands, analyzing sensitized protein bands by LC-MS, screening the specific peptide fragments of sensitized proteins; extracting proteins from a royal jelly sample, digesting the proteins by enzymes, and quantitatively measuring the sensitized proteins by LC-MS/MS. The provided sensitized protein quantitative method has the advantages of high specificity and sensitivity, good repeatability, high accuracy, and wide linear range, and is capable of precisely and quantitatively analyzing a sensitized protein in a sample.